The latest event in the nearly four-year collaboration between Gilead Sciences, Inc. and Arcus Biosciences, Inc. saw Gilead increase its equity stake in its partner to approximately 33% in a transaction that Arcus said would give it financial runway into 2027. The two companies also announced that they are ending enrollment in a chemotherapy-free lung cancer trial to focus on other Phase III studies, while Arcus said it will conduct Phase III development of CD73 inhibitor quemliclustat in pancreatic cancer on its own.
Key Takeaways
-
Gilead increases its stake in Arcus, by paying $320m at a 37% premium to reach 33% equity in its partner.
Gilead announced after market close on 29 January that it will make a $320m equity investment in Arcus, increasing its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?